Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
China
Henan Cancer Hospital, Zhengzhou, Henan The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi Shandong Cancer Hospital, Jinan, Shandong The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang The Institute of Hematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences, Tianjing